Latham & Watkins Advises Zevra Therapeutics in Successful Activism Defense Resulting in Election of Company’s Director Nominees at Annual Meeting

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Elections following the company’s 2025 Annual Meeting of Stockholders, stockholders have voted to re-elect Wendy L. Dixon, PhD, and Tamara A. Favorito to the company’s Board of Directors as Class I Directors to serve until the 2028 Annual Meeting.

Latham & Watkins LLP represents Zevra in connection with the proxy contest with a multidisciplinary corporate team led by partners Nathan Ajiashvili, Josh Dubofsky, Global Co-Chair of Latham’s Shareholder Activism & Takeover Defense Practice, Jenna Cooper, Global Vice Chair of Latham’s Public Company & Board Representation Practice, and Michele Anderson, with associates Naseem Faqihi Alawadhi, Maya Rahwanji, Ashley Lee, and Kristen Ierardi.